13D Filing: Lansdowne Partners and Summit Therapeutics PLC (ADR) (SMMT)

Page 1 of 8

Summit Therapeutics PLC (ADR) (NASDAQ:SMMT): Alex Snow’s Lansdowne Partners filed an amended 13D.

You can check out Lansdowne Partners’ latest holdings and filings here.

Please follow Lansdowne Partners (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Lansdowne Partners or update its stock holdings.

Follow Brian Heyworth's Lansdowne Partners

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Lansdowne Partners (UK) L 0 19,060,500 0 19,060,500 19,060,500 25.91%
Lansdowne Developed Markets Master Fund Limited 0 19,060,500 0 19,060,500 19,060,500 25.91%

Follow Brian Heyworth's Lansdowne Partners

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13D/A

Amendment No. 3

INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (a) AND

AMENDMENTS THERETO FILED PURSUANT TO
13d-2 (a)

Summit Therapeutics PLC
(Name of Issuer)
American Depositary Shares and Ordinary Shares, par value £0.01 per share
(Title of Class of Securities)
86627R102
(CUSIP Number)

Hugh Orange

c/o Lansdowne Partners (UK) LLP

15 Davies Street

London W1K 3AG

England

44-20-7290-5500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
December
29, 2017
(Date of Event Which Requires Filing of this Statement)

Follow Summit Therapeutics Inc. (NASDAQ:SMMT)

Page 1 of 8